Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
Author Information
Author(s): Stenner Max-Philipp, Waschbisch Anne, Buck Dorothea, Doerck Sebastian, Einsele Hermann, Toyka Klaus V., Wiendl Heinz
Primary Institution: Julius-Maximilians University, Wuerzburg, Germany
Hypothesis
How does Natalizumab therapy affect Foxp3+ T regulatory cells in multiple sclerosis patients?
Conclusion
Natalizumab does not alter the frequency or suppressive function of Foxp3+ T regulatory cells in multiple sclerosis patients.
Supporting Evidence
- Foxp3+ Tregs had lower levels of CD49d and bound less Natalizumab compared to non-regulatory T cells.
- Natalizumab blocked the transmigration of Foxp3+ Tregs similarly to non-regulatory T cells.
- The frequency of peripheral blood Tregs was unaffected by Natalizumab treatment.
- Natalizumab did not restore the impaired function of Tregs in MS patients.
Takeaway
This study found that a treatment called Natalizumab doesn't change the number or effectiveness of certain immune cells that help control inflammation in people with multiple sclerosis.
Methodology
The study used in vitro and ex vivo experiments with T cells from healthy donors and MS patients to assess the effects of Natalizumab on Tregs.
Limitations
The study did not analyze the effects of Natalizumab on Tregs in the cerebrospinal fluid due to technical and ethical reasons.
Participant Demographics
Participants included relapsing-remitting multiple sclerosis patients and healthy donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website